Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Zheng (South San Francisco, United States of America), Y. Guan (South San Francisco, United States of America), Y. Gao (Shanghai, China), L. Liu (Shanghai, China), L. Abuqayyas (Cambridge, United States of America), Å. Hellqvist (Gothenburg, Sweden), K. Bowen (Gaithersburg, United States of America), G. Colice (Gaithersburg, United States of America), A. Macdonald (Cambridge, United Kingdom). Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma. 884

Member's Comments

No comment yet.

Related content which might interest you: Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection Source: International Congress 2018 – Asthma management Year: 2018 Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Population pharmacokinetic analysis of fluticasone propionate data from adult and pediatric subjects with asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Dealing with missing longitudinal FEV1 observations when used as time-dependent covariate data in survival analysis for COPD patients within a regional UK population-level database Source: International Congress 2015 – Epidemiology of respiratory disease Year: 2015 Occupational exposure as a predictor of asthma exacerbation – a multicenter multivariate logistical analysis. Source: Virtual Congress 2021 – Occupational rhinitis and asthma Year: 2021 Efficacy of roflumilast in patients with a history of frequent exacerbations: Pooled data from pivotal 12-month studies Source: Annual Congress 2010 - COPD: management Year: 2010 Meta-analysis on dose-response relationship of inhaled steroids must be done in homogenous asthma populations Source: Eur Respir J 2004; 24: 513 Year: 2004 A realistic study assessing inhaled treatment compliance in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 25s Year: 2001 Budesonide/formoterol adjustable maintenance dosing and fixed dosing in adolescents with asthma: a Swedish study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003 A Markov model based on COPD disease severity to analyse the results from tiotropium trials Source: Eur Respir J 2002; 20: Suppl. 38, 125s Year: 2002 Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 A weight-based exacerbation dose-response analysis of mepolizumab in severe asthma with eosinophilic phenotype Source: International Congress 2016 – Asthma management Year: 2016 Biomarker measurement in asthma patients receiving biologic therapy: a real-world retrospective study Source: International Congress 2018 – Eosinophils in airway disease Year: 2018 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003 Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Efficacy of multivariate analysis in differentiating between asthma and COPD in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 275s Year: 2005 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019